PD-L1 Subgroup Benefits Most From Neoadjuvant Immunotherapy in Early Breast Cancer
Lajos Pusztai reviews the two 'potentially paradigm-shifting trials'
Source: medpagetoday.com
Page 4 - Greg Laub News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Greg Laub. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Greg Laub Today - Breaking & Trending Today
Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma
Study results show impressive efficacy, favorable safety profile in the second line
Source: medpagetoday.com
Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients
Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study
Source: medpagetoday.com
Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer
But sequencing of ADCs such as datopotamab deruxtecan remains an unanswered question
Source: medpagetoday.com
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL
Approach could allow for a response-adapted reduction of CHOP
Source: medpagetoday.com